

CENTENE PHARMACY AND THERAPEUTICS
THERAPEUTIC CLASS MATRIX
GPI Code 45: Respiratory Agents, Miscellaneous
1Q18 January - February

Review Time Frame: November 2016 – October 2017

Background:

Miscellaneous respiratory agents include drugs used for the prevention and treatment of various conditions and diseases relating to the lungs to improve pulmonary function, including, but not limited to, cystic fibrosis and pulmonary fibrosis.

New Drugs:

Date of Approval	Drug Name	FDA-Approved Indication(s)	Approval Type	Commercial Availability
05/01/17	Talc (Steritalc)	<ul style="list-style-type: none"> • To decrease the recurrence of malignant pleural effusions in symptomatic patients following maximal drainage of the pleural effusion. • In adults to decrease the recurrence of pneumothorax. 	<input type="checkbox"/> New entity <input checked="" type="checkbox"/> New formulation <i>(powder: 2, 3, and 4 grams)</i> <input type="checkbox"/> New combination <input type="checkbox"/> New indication <input type="checkbox"/> First time generic <input checked="" type="checkbox"/> New brand (existing agent)	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
01/11/17	Pirfenidone (Esbriet)	Treatment of idiopathic pulmonary fibrosis	<input type="checkbox"/> New entity <input checked="" type="checkbox"/> New formulation <i>(film-coated tablets)</i> <input type="checkbox"/> New combination <input type="checkbox"/> New indication <input type="checkbox"/> First time generic <input type="checkbox"/> New brand (existing agent)	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

Discontinued Drugs:

None identified.

FDA Safety Warnings:

None identified.

REVIEW RECOMMENDATION

There is no existing clinical guidance for this drug class.

References:

CENTENE PHARMACY AND THERAPEUTICS
THERAPEUTIC CLASS MATRIX
GPI Code 45: Respiratory Agents, Miscellaneous
1Q18 January - February

Review Time Frame: November 2016 – October 2017

1. US Food and Drug Administration. Available at: www.fda.gov. Accessed November 16, 2017.
2. Raghu G, Rochweg B, Zhang Y, et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. *American Journal of Respiratory and Critical Care Medicine*. 2015 July 15; 192(2):e3-19.
3. Mogayzel PJ Jr, Naureckas ET, Robinson KA, et. al. Cystic Fibrosis Pulmonary Guidelines: Chronic Medications for Maintenance of Lung Health. *American Journal of Respiratory and Critical Care Medicine*. 2013 April; 187(7):680-9.